CCS1477 and its application
CellCentric’s first-in-class drug is a small molecule that inhibits the conserved bromodomain of p300 and CBP. It was developed by the company from initial hits through to an optimised compound and clinical candidate. It is formulated as a capsule taken orally.
The compound has been evaluated extensively pre-clinically, demonstrating its impact on p300/CBP inhibition in vivo. P300/CBP affects the expression of the androgen receptor (AR), as well as its variants. It also impacts MYC and IRF4. This mechanism of action links through to the treatment of specific cancer types; late stage, drug resistant, prostate cancer and haematological malignancies (including multiple myeloma and acute myeloid leukaemia).
Certain tumours over-express AR and MYC. Other tumours have loss of function mutations in either p300 or CBP. These molecularly driven cancer types can be specifically targeted with CCS1477. These tumours can be wide ranging, and include lymphomas, lung, bladder and breast cancers.